Selected videos of the 55th ASCO Congress

31 May-4 June 2019, Chicago, USA

“Caring for every cancer patient & learning from every cancer patient” 
a far-reaching theme of the 2019 ASCO Annual Meeting — inspires both clinical oncologists and physician/scientists to value the importance of each cancer patient encounter. While Phase 3 clinical trials are vital to the evidence-based FDA-approval process, it is the oncologist at the bedside who makes the ultimate decisions on how, and with precisely what drugs, an individual patient will be treated. Thus, contemporary oncologists assume responsibilities for continuing education and clinical research in this Age of Precision Medicine and Tumour-Targeted Cancer Gene Therapy. The ASCO annual meetings are valuable in this regard; for it is within these topical meetings that medical oncologists gather from around the world to share clinical experiences, exchange clinical insights, and introduce innovative therapies. In such networking, medical and scientific visions are broadly shared and ultimately translated into the safe and effective medicines of the future. Indeed, the promise of Precision Medicine has come of age with the development of tumour-targeted viral vectors, genetic profiling, next generation sequencing, and complementary biomarkers.


Dr Erlinda M. Gordon and Dr Sant P. Chawla

The ASCO2019 Medicom Conference Report includes 8 Editor selected ASCO2019 Congress videos.

  • Breast cancer
  • Lung Cancer
  • Multiple Myeloma
  • Sarcoma
  • Gastrointestinal Cancers 
  • Genitourinary Cancer

Breast Cancer

Lung Cancer

Phase III MONALEESA-7 trial of premonopausal patients with HR+/HER2-advanced breast cancer (ABC) treated with endocrine therapy +/- ribociclib: Overall survival (OS) results

Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.

Multiple Myeloma

Insurance status and survival of multiple myeloma (MM) patients.



A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox +PBO in patients (pts) with advanced soft tissue sarcomas (STS).

Gastrointestinal Cancers

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

Genitourinary Cancer - Prostate Cancer

Olaparib as maintanance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.

Gastrointestinal Cancers

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzautamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Genitourinary Cancer - Prostate Cancer

EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.